Endo Releases First Environmental, Social and Governance Report
Oct 06, 2020, 14:34 ET
DUBLIN, Oct. 6, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the release of its first Environmental, Social and Governance (ESG) report, titled 2019 Corporate Responsibility Report: Helping Everyone We Serve Live Their Best Life. It summarizes the Company's current efforts to responsibly serve customers and patients, team members and other stakeholders, and it provides a starting point to build and further strengthen Endo's ESG programs and practices.
"Our ESG report showcases Endo's commitment to deliver on our company vision—helping everyone we serve live their best life," said Blaise Coleman, President and CEO of Endo. "One of our three strategic priorities is to be a force for good as this embodies our responsibility for maintaining a culture of compliance and ethics, working to make medicines more accessible to people who need them, and upholding our goal of promoting diversity, equity and inclusion in all we do."
Endo's report covers the following four areas:
- Our Business Practices – Adhering to Endo's business ethics and code of conduct, team members take accountability, act as owners and do the right thing even when no one is watching.
- Our Team – Endo offers comprehensive programs to provide a safe working environment, drive career development, build an engaging workplace culture and encourage wellness.
- Our Customers – Driven by a culture of quality and integrity, all Endo team members are accountable to do their part to help patients get the medicines and products they need.
- Our World – Endo strives to operate in a responsible manner that minimizes environmental risks and impact while promoting the safe, efficient and responsible use of global resources.
To develop this four-pillar framework, Endo engaged internal stakeholder groups and consulted external resources, including the Sustainability Accounting Standards Board (SASB) framework. Endo is using applicable SASB metrics to measure its performance. The Company plans to continue to report on its corporate responsibility efforts on an annual basis and plans to issue its next report during the second quarter of 2021.
Find the full report on https://www.endo.com/our-responsibility/overview.
About Endo International plc
Endo International plc (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the relevant Canadian securities legislation, including, but not limited to, the statements by Mr. Coleman. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward-looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with the Securities and Exchange Commission and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval, including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, and as otherwise enumerated herein or therein, could affect Endo's future results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in this communication. The forward-looking statements in this press release are qualified by these risk factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.
SOURCE Endo International plc
